Dr. Reddy's Laboratories Ltd
RDY · Healthcare
$12.17
Cargando gráfico…
Noticias
Últimos titulares de esta acción
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories
The global papulopustular rosacea market is projected to grow steadily through 2035, driven by rising prevalence, improved diagnosis, and demand for safer non-antibiotic treatments. Advanced therapies including topical ivermectin, azelaic acid, and minocycline foam are reshaping care. Key players include Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Laboratories, with growth supported by dermatology R&D, innovative drug delivery, and telemedicine despite challenges like high treatment costs and underdiagnosis.
DR. REDDY’S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Dr. Reddy's Laboratories following the company's disclosure of a ₹2.4 billion provision for out-of-spec semaglutide batches in Q1 FY2027 earnings. The stock fell 9% on the news, though management stated there was no patient safety impact or regulatory filing impact.